Aptahem AB (XSAT:APTA) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


XSAT:APTA Aptahem AB XSAT:APTA
30 GF Score
Price kr0.50
! 2 Warning Signs
View Full Analysis

What is Aptahem AB Research & Development?

Aptahem AB XSAT:APTA -9.09% 30 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aptahem AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Aptahem AB  (XSAT:APTA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aptahem AB Research & Development Related Terms

Aptahem AB Research & Development Historical Data

* Premium members only.

The historical data trend for Aptahem AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptahem AB Research & Development Chart

Aptahem AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aptahem AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:APTA
30GF Score
Aptahem AB XSAT:APTA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Aptahem AB (XSAT:APTA) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aptahem AB and its competitors.
Is Aptahem AB's Research & Development too high?
Aptahem AB's current Research & Development is kr0.00 Mil. Overall, Aptahem AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's Research & Development compare to VRTX and REGN?
Aptahem AB's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aptahem AB and its competitors. Aptahem AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Aptahem AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score

Get the complete analysis for XSAT:APTA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.50
Price